Navigation Links
Notre Dame researchers offer new insights on cancer cell signaling
Date:7/15/2013

A pair of studies by a team of University of Notre Dame researchers led by Crislyn D'Souza-Schorey, professor of biological sciences, sheds light on a biological process which is activated across a vast range of malignancies.

Wnt proteins are a large family of proteins that active signaling pathways (a set of biological reactions in a cell) to control several vital steps in embryonic development. In adults, Wnt-mediated functions are frequently altered in many types of cancers and, specifically, within cell subpopulations that possess stem cell-like properties.

In two studies, one in the recent issue of the journal Molecular and Cellular Biology and a second, published earlier this year in Science Signaling, D'Souza-Schorey's laboratory reports on the importance of the protein "ARF6" in Wnt signaling.

The best documented role of Wnt is its triggering of the canonical (idealized or generalized) signaling pathway that leads to the stabilization of a protein called beta-catenin. This in turn leads to activation of various target genes that result in changes in a wide spectrum of cell behaviors.

"We have had a long standing interest in understanding the role of ARF6 in cell behavior," D'Souza-Schorey said. "ARF6 is an interesting molecule at the nexus of several important cell-signaling pathways. Our interest in this line of investigation has only been heightened by emerging reports from many labs that ARF6 activity is dramatically increased in several cancers. In our most recent study, we show how ARF6 can propagate Wnt signaling leading to proliferative phenotypes that are frequently seen in epithelial tumors (a growth of irregularly-shaped cells on the outer membrane of an organ or gland)."

In the paper published in Science Signaling, the laboratory collaborated with researchers at the University of Utah to document the importance of ARF6-regulated activation of canonical Wnt signaling in the spread of melanoma. The study showed that a small molecule that prevents ARF6 activation could stop tumor invasion and the spread of the cancer.

"The relevance of Wnt signaling in human cancers in manifest by the frequency with which this pathway is aberrantly activated across a wide range of malignancies," D'Souza-Schorey said. "Given the number of Wnts, Wnt signaling has been difficult to target therapeutically. It is important to note that while there are many mechanisms that drive aberrant Wnt/beta-catenin signaling in diverse cancers, these different mechanisms nearly always occur in a mutually exclusive manner. Thus, a better understanding of mechanisms involved in Wnt signaling transduction offers several target molecules for cancer drug development."

Notre Dame graduate students James Clancy, Oscar Pellon-Cardenas, Alanna Sedgwick and Henriette Uwimphuwe were co-authors on the two studies from D'Souza-Schorey's laboratory.


'/>"/>

Contact: Crislyn D'Souza-Schorey
cdsouzas@nd.edu
574-631-3735
University of Notre Dame
Source:Eurekalert

Related medicine news :

1. Notre Dame and Harper researchers developing novel method to test for HPV and oral cancers
2. New Notre Dame paper offers insights into how cancer cells avoid cell death
3. Notre Dame researchers scoring a win-win with novel set of concussion diagnostic tools
4. Notre Dame researchers paper examines the biology of tumor-derived microvesicles
5. Nanoparticles engineered at Notre Dame promise to improve blood cancer treatment
6. Use redistricting maps to make organ allocation more equitable, Johns Hopkins researchers advocate
7. Sanford-Burnham researchers develop novel nanoparticle to deliver powerful RNA interference drugs
8. Researchers investigate mechanism of Alzheimers therapy
9. Researchers pinpoint sources of fibrosis-promoting cells that ravage organs
10. Researchers use immunocytochemistry to determine ALK status
11. Researchers find 2 new methods to determine ALK status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: